Lindsay A. Rein, MD, reviews exciting data presented at this year’s ASH meeting, focusing on chronic myeloid leukemia (CML) and the recent approval of asciminib, a novel agent for first-, second-, and ...

Lead CML researcher discusses the evolution of a groundbreaking treatment and its effect on patient survival. When imatinib (Gleevec; Novartis), the first-ever tyrosine kinase inhibitor, made its ...

Merck & Co. has agreed to acquire Terns Pharmaceuticals for approximately $6.7 billion, in a deal designed to bolster the ...

Finding a cure for a rare type of blood cancer could be accelerated by a new virtual platform that allows researchers easy access to data from patient samples generated by laboratories around the ...

Conference MDAngle offers personal perspectives from conference attendees, showcasing their anticipation, quick takeaways, and insights into how the presented research will affect their patients. Dr ...

Gleevec, a cancer drug first approved for sale in 2001, has dramatically changed the lives of people with chronic myeloid leukemia. This form of cancer was once regarded as very difficult to combat, ...